Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and ...

TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 ...

The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and datopotamab deruxtecan (Dato-DXd), a TROP2 directed ADC, which are being jointly developed and commercialized globally ...

Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment. Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast ...

Capital structure describes the mix of a firm's long-term capital—a mix of debt and equity—that it uses to fund its ongoing operations and future growth. A company's capital structure is ...

MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective in a phase 3 lung cancer study that reinforces its potential as a new treatment option for patients after first-line tr The ...

Medscape Medical News, May 19, 2023 ESMO Breast Cancer 2023 Patritumab Deruxtecan Shows Promise for Breast Cancer A single dose of patritumab deruxtecan provoked a response in nearly one third of ...

This morning, the Japanese drugmaker reported updated clinical results from two clinical trials of its HER3-targeted ADC patritumab deruxtecan in metastatic breast cancer and non-small cell lung ...

The study of stellar structure and evolution is dedicated to understanding how stars change over their lifetimes, including the processes that shape them on the inside. Studying fluctuations in light ...